- Plus Therapeutics press release ( NASDAQ: PSTV ): FY GAAP EPS of -$0.77 misses by $0.02 .
- Revenue of $0.22M misses by $0.5M .
- The Company’s cash balance was $18.1 million at December 31, 2022, compared to $18.4 million at December 31, 2021.
- The Company believes that current cash on hand, anticipated funding from both the National Institutes of Health and CPRIT, and existing discretionary capital sources are sufficient to fund both its currently planned and anticipated overhead and development expenses through 2025.
For further details see:
Plus Therapeutics GAAP EPS of -$0.77 misses by $0.02, revenue of $0.22M misses by $0.5M